612 related articles for article (PubMed ID: 25110254)
1. An update on anti-TNF agents in ulcerative colitis.
Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
[TBL] [Abstract][Full Text] [Related]
2. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
3. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis.
Huang X; Lv B; Jin HF; Zhang S
Eur J Clin Pharmacol; 2011 Aug; 67(8):759-66. PubMed ID: 21691804
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.
Thorlund K; Druyts E; Mills EJ; Fedorak RN; Marshall JK
J Crohns Colitis; 2014 Jul; 8(7):571-81. PubMed ID: 24491514
[TBL] [Abstract][Full Text] [Related]
6. Golimumab: clinical update on its use for ulcerative colitis.
Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
[TBL] [Abstract][Full Text] [Related]
7. [Golimumab Therapy in Ulcerative Colitis].
Moon W
Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
9. Positioning Therapy for Ulcerative Colitis.
Grinspan A; Kornbluth A
Curr Gastroenterol Rep; 2015 Aug; 17(8):29. PubMed ID: 26143627
[TBL] [Abstract][Full Text] [Related]
10. Golimumab for the treatment of ulcerative colitis.
Flamant M; Paul S; Roblin X
Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
[TBL] [Abstract][Full Text] [Related]
12. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis.
Fratila OC; Craciun C
J Gastrointestin Liver Dis; 2010 Jun; 19(2):147-53. PubMed ID: 20593047
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
[TBL] [Abstract][Full Text] [Related]
14. Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis.
Galván-Banqueri M; Vega-Coca MD; Castillo-Muñoz MA; Beltrán Calvo C; Molina López T
Farm Hosp; 2015 Mar; 39(2):80-91. PubMed ID: 25817087
[TBL] [Abstract][Full Text] [Related]
15. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
Vande Casteele N; Khanna R
Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
[TBL] [Abstract][Full Text] [Related]
17. Update on anti-tumor necrosis factor agents in Crohn disease.
Singh S; Pardi DS
Gastroenterol Clin North Am; 2014 Sep; 43(3):457-78. PubMed ID: 25110253
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
20. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
Toor K; Druyts E; Jansen JP; Thorlund K
J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
